Keros Therapeutics

KROSNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$232.573 M

$11.73 +2.18%

Close of 22 Sept 2026

Revenue

$243.9M

#2222 by revenue

Earnings

$87.0M

#1361 by earnings

Shares outstanding

19,827,188

Latest filing cover page

P/E ratio

2.7

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#256Siga TechnologiesSIGA$234.2M
#257Natures Sunshine ProductsNATR$232.6M
#258Keros TherapeuticsKROS$232.6M
#259Whitehawk TherapeuticsWHWK$230.3M
#260Cue BiopharmaCUE$224.5M

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Keros Therapeutics, worth $10.3K. Grants and option exercises are excluded.

Jean Jacques Bienaime$10.3K
1,000 shares at $10.27 on 17 Aug 2026 · filed 19 Aug 2026

What if Keros Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,524,874

Per share 129,998× higher

Bitcoin $1.74T

$87,841.76

Per share 7,489× higher

Nvidia $5.52T

$278,192.10

Per share 23,716× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Keros Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.